A Gregory Sorensen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1317237/publications.pdf

Version: 2024-02-01

162 papers	27,842 citations	10070 75 h-index	7043 159 g-index
166 all docs	166 docs citations	166 times ranked	25770 citing authors

#	Article	IF	Citations
1	Robust breast cancer detection in mammography and digital breast tomosynthesis using an annotation-efficient deep learning approach. Nature Medicine, 2021, 27, 244-249.	15.2	187
2	PSY3-1 Artificial intelligence in oncology imaging. Annals of Oncology, 2021, 32, S241.	0.6	0
3	Evaluation of Combined Artificial Intelligence and Radiologist Assessment to Interpret Screening Mammograms. JAMA Network Open, 2020, 3, e200265.	2.8	236
4	Ensemble of Convolutional Neural Networks Improves Automated Segmentation of Acute Ischemic Lesions Using Multiparametric Diffusion-Weighted MRI. American Journal of Neuroradiology, 2019, 40, 938-945.	1.2	41
5	Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686. Neuro-Oncology, 2018, 20, 1400-1410.	0.6	27
6	NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma. Journal of Neuro-Oncology, 2017, 131, 193-199.	1.4	55
7	ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI. Clinical Cancer Research, 2016, 22, 5079-5086.	3.2	99
8	Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: A multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma. International Journal of Oncology, 2015, 46, 1883-1892.	1.4	57
9	Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial. Neuro-Oncology, 2015, 17, 1148-1156.	0.6	108
10	Gadobutrol in the central nervous system at three doses: Results from a phase II, randomized, multicenter trial. Journal of Magnetic Resonance Imaging, 2014, 39, 410-418.	1.9	2
11	Low Incidence of Pseudoprogression by Imaging in Newly Diagnosed Glioblastoma Patients Treated With Cediranib in Combination With Chemoradiation. Oncologist, 2014, 19, 75-81.	1.9	16
12	Validity of Acute Stroke Lesion Volume Estimation by Diffusion-Weighted Imagingâ€“Alberta Stroke Program Early Computed Tomographic Score Depends on Lesion Location in 496 Patients With Middle Cerebral Artery Stroke. Stroke, 2014, 45, 3583-3588.	1.0	36
13	Vessel calibreâ€”a potential MRI biomarker of tumour response in clinical trials. Nature Reviews Clinical Oncology, 2014, 11, 566-584.	12.5	55
14	Pretreatment Bloodâ€“Brain Barrier Damage and Post-Treatment Intracranial Hemorrhage in Patients Receiving Intravenous Tissue-Type Plasminogen Activator. Stroke, 2014, 45, 2030-2035.	1.0	73
15	Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. Nature Medicine, 2013, 19, 1178-1183.	15.2	212
16	Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677. Neuro-Oncology, 2013, 15, 936-944.	0.6	48
17	Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study. Neuro-Oncology, 2013, 15, 945-954.	0.6	74
18	Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma. Journal of Clinical Oncology, 2013, 31, 3212-3218.	0.8	489

#	Article	IF	Citations
19	Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 19059-19064.	3.3	303
20	Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. Journal of Clinical Investigation, 2013, 123, 3659-3663.	3.9	147
21	Case 17-2012. New England Journal of Medicine, 2012, 366, 2112-2120.	13.9	3
22	Neurologic 3D MR Spectroscopic Imaging with Low-Power Adiabatic Pulses and Fast Spiral Acquisition. Radiology, 2012, 262, 647-661.	3.6	63
23	Increased Survival of Glioblastoma Patients Who Respond to Antiangiogenic Therapy with Elevated Blood Perfusion. Cancer Research, 2012, 72, 402-407.	0.4	264
24	Detection of 2-Hydroxyglutarate in IDH -Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance Spectroscopy. Science Translational Medicine, 2012, 4, 116ra4.	5.8	367
25	Diffusion Tensor Imaging Shows Structural Remodeling of Stroke Mirror Region: Results from a Pilot Study. European Neurology, 2012, 67, 370-376.	0.6	21
26	Fast radioâ€frequency enforced steady state (FRESS) spin echo MRI for quantitative T₂ mapping: minimizing the apparent repetition time (TR) dependence for fast T₂ measurement. NMR in Biomedicine, 2012, 25, 189-194.	1.6	14
27	Correlation chemical shift imaging with lowâ€power adiabatic pulses and constantâ€density spiral trajectories. NMR in Biomedicine, 2012, 25, 195-209.	1.6	34
28	Effects of cediranib, a VEGF signaling inhibitor, in combination with chemoradiation on tumor blood flow and survival in newly diagnosed glioblastoma.. Journal of Clinical Oncology, 2012, 30, 2009-2009.	0.8	7
29	Incidental Findings in Brain MRI Research: What Do We Owe Our Subjects?. Journal of the American College of Radiology, 2011, 8, 848-852.	0.9	20
30	Transient Ischemic Attack: Definition, Diagnosis, and Risk Stratification. Neuroimaging Clinics of North America, 2011, 21, 303-313.	0.5	46
31	Sensitivity of MRI Tumor Biomarkers to VEGFR Inhibitor Therapy in an Orthotopic Mouse Glioma Model. PLoS ONE, 2011, 6, e17228.	1.1	27
32	T₁- and T₂*-Dominant Extravasation Correction in DSC-MRI: Part IIâ€”Predicting Patient Outcome after a Single Dose of Cediranib in Recurrent Glioblastoma Patients. Journal of Cerebral Blood Flow and Metabolism, 2011, 31, 2054-2064.	2.4	35
33	T₁- and T*₂-Dominant Extravasation Correction in DSC-MRI: Part Iâ€”Theoretical Considerations and Implications for Assessment of Tumor Hemodynamic Properties. Journal of Cerebral Blood Flow and Metabolism, 2011, 31, 2041-2053.	2.4	100
34	Diffusion and Diffusion Tensor Imaging in Brain Cancer. Seminars in Radiation Oncology, 2011, 21, 141-146.	1.0	38
35	DWI-FLAIR mismatch for the identification of patients with acute ischaemic stroke within 4Â·5 h of symptom onset (PRE-FLAIR): a multicentre observational study. Lancet Neurology, The, 2011, 10, 978-986.	4.9	468
36	Vagus nerve stimulation reduces infarct size in rat focal cerebral ischemia: An unlikely role for cerebral blood flow. Brain Research, 2011, 1392, 110-115.	1.1	68

#	Article	IF	Citations
37	Fast multislice pHâ€weighted chemical exchange saturation transfer (CEST) MRI with Unevenly segmented RF irradiation. Magnetic Resonance in Medicine, 2011, 65, 588-594.	1.9	73
38	Diffusion imaging with prospective motion correction and reacquisition. Magnetic Resonance in Medicine, 2011, 66, 154-167.	1.9	63
39	Simulation and optimization of pulsed radio frequency irradiation scheme for chemical exchange saturation transfer (CEST) MRIâ€"demonstration of pHâ€weighted pulsedâ€amide proton CEST MRI in an animal model of acute cerebral ischemia. Magnetic Resonance in Medicine, 2011, 66, 1042-1048.	1.9	75
40	In vivo ³¹P spectroscopy by fully adiabatic extended image selected in vivo spectroscopy: A comparison between 3 T and 7 T. Magnetic Resonance in Medicine, 2011, 66, 923-930.	1.9	40
41	QUantitative Imaging of eXtraction of oxygen and TIssue consumption (QUIXOTIC) using venularâ€targeted velocityâ€selective spin labeling. Magnetic Resonance in Medicine, 2011, 66, 1550-1562.	1.9	141
42	Bimodal Thrombus Imaging: Simultaneous PET/MR Imaging with a Fibrin-targeted Dual PET/MR Probeâ€"Feasibility Study in Rat Model. Radiology, 2011, 258, 812-820.	3.6	86
43	MRI-Assisted PET Motion Correction for Neurologic Studies in an Integrated MR-PET Scanner. Journal of Nuclear Medicine, 2011, 52, 154-161.	2.8	167
44	Glioblastoma Recurrence after Cediranib Therapy in Patients: Lack of â€œReboundâ€•Revascularization as Mode of Escape. Cancer Research, 2011, 71, 19-28.	0.4	186
45	Lower Hemoglobin Correlates with Larger Stroke Volumes in Acute Ischemic Stroke. Cerebrovascular Diseases Extra, 2011, 1, 44-53.	0.5	41
46	Age-Dependent Susceptibility to Infarct Growth in Women. Stroke, 2011, 42, 947-951.	1.0	24
47	Prediction of Early Stroke Risk in Transient Symptoms With Infarction. Stroke, 2011, 42, 2186-2190.	1.0	30
48	Serial Magnetic Resonance Spectroscopy Reveals a Direct Metabolic Effect of Cediranib in Glioblastoma. Cancer Research, 2011, 71, 3745-3752.	0.4	46
49	Use of in Vivo Two-dimensional MR Spectroscopy to Compare the Biochemistry of the Human Brain to That of Glioblastoma. Radiology, 2011, 259, 540-549.	3.6	36
50	Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma. American Journal of Neuroradiology, 2011, 32, 1978-1985.	1.2	460
51	Lowâ€power adiabatic sequences for in vivo localized twoâ€dimensional chemical shift correlated MR spectroscopy. Magnetic Resonance in Medicine, 2010, 64, 1542-1556.	1.9	42
52	Angiopoietin-2 Interferes with Anti-VEGFR2â€"Induced Vessel Normalization and Survival Benefit in Mice Bearing Gliomas. Clinical Cancer Research, 2010, 16, 3618-3627.	3.2	125
53	In vivo validation of MRI vessel caliber index measurement methods with intravital optical microscopy in a U87 mouse brain tumor model. Neuro-Oncology, 2010, 12, 341-350.	0.6	46
54	Toward Implementing an MRI-Based PET Attenuation-Correction Method for Neurologic Studies on the MR-PET Brain Prototype. Journal of Nuclear Medicine, 2010, 51, 1431-1438.	2.8	413

#	Article	IF	Citations
55	Science to Practice: Blood-Brain Barrier Leakageâ€"One Size Does Not Fit All. Radiology, 2010, 257, 303-304.	3.6	5
56	Advances in Imaging 2009. Stroke, 2010, 41, e91-2.	1.0	0
57	Molecular MRI of Intracranial Thrombus in a Rat Ischemic Stroke Model. Stroke, 2010, 41, 1271-1277.	1.0	52
58	Phase II Study of Cediranib, an Oral Panâ€"Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma. Journal of Clinical Oncology, 2010, 28, 2817-2823.	0.8	489
59	Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group. Journal of Clinical Oncology, 2010, 28, 1963-1972.	0.8	3,222
60	Comatose Patients with Cardiac Arrest: Predicting Clinical Outcome with Diffusion-weighted MR Imaging. Radiology, 2009, 252, 173-181.	3.6	166
61	Advances in Imaging. Stroke, 2009, 40, e313-4.	1.0	5
62	C linical- and I maging-Based P rediction of Stroke Risk After Transient Ischemic Attack. Stroke, 2009, 40, 181-186.	1.0	117
63	A â€œVascular Normalization Indexâ€•as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients. Cancer Research, 2009, 69, 5296-5300.	0.4	369
64	Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2. New England Journal of Medicine, 2009, 361, 358-367.	13.9	446
65	Angiogenesis as a Therapeutic Target in Malignant Gliomas. Oncologist, 2009, 14, 621-636.	1.9	106
66	Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma. Journal of Neuro-Oncology, 2009, 93, 61-77.	1.4	48
67	Feasibility of NIRS in the Neurointensive Care Unit: A Pilot Study in Stroke Using Physiological Oscillations. Neurocritical Care, 2009, 11, 288-295.	1.2	44
68	Anti-vascular endothelial growth factor therapy for malignant glioma. Current Neurology and Neuroscience Reports, 2009, 9, 254-262.	2.0	13
69	Biomarkers of response and resistance to antiangiogenic therapy. Nature Reviews Clinical Oncology, 2009, 6, 327-338.	12.5	541
70	Vagus nerve stimulation reduces infarct size in rat focal cerebral ischemia. Neuroscience Letters, 2009, 459, 147-151.	1.0	75
71	VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nature Reviews Clinical Oncology, 2009, 6, 229-236.	12.5	175
72	RTOG 0625: A phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM). Journal of Clinical Oncology, 2009, 27, 2011-2011.	0.8	18

#	Article	IF	Citations
73	A phase II study of XL184 in patients (pts) with progressive glioblastoma multiforme (GBM) in first or second relapse. Journal of Clinical Oncology, 2009, 27, 2047-2047.	0.8	29
74	Use of neurovascular imaging in GBM patients (pts) to quantify early physiologic changes after treatment with XL184, an inhibitor of multiple receptor tyrosine kinases: Results from a phase II study. Journal of Clinical Oncology, 2009, 27, 2048-2048.	0.8	3
75	Phase I trial of vatalanib (PTK787) in combination with standard radiation and temozolomide in patients with newly diagnosed glioblastoma. Journal of Clinical Oncology, 2009, 27, 2035-2035.	0.8	3
76	Using the wild bootstrap to quantify uncertainty in diffusion tensor imaging. Human Brain Mapping, 2008, 29, 346-362.	1.9	96
77	The Use of Imaging in the Early Development of Neuropharmacological Drugs: A Survey of Approved NDAs. Clinical Pharmacology and Therapeutics, 2008, 84, 69-74.	2.3	36
78	Response criteria for glioma. Nature Clinical Practice Oncology, 2008, 5, 634-644.	4.3	171
79	Severity of Leukoaraiosis and Susceptibility to Infarct Growth in Acute Stroke. Stroke, 2008, 39, 1409-1413.	1.0	155
80	Interexaminer Difference in Infarct Volume Measurements on MRI. Stroke, 2008, 39, 1171-1176.	1.0	53
81	Middle Cerebral Artery Infarcts Encompassing the Insula Are More Prone to Growth. Stroke, 2008, 39, 373-378.	1.0	44
82	Perfusion MR Imaging: Moving Forward. Radiology, 2008, 249, 416-417.	3.6	19
83	Advances in Imaging 2007. Stroke, 2008, 39, 276-278.	1.0	8
84	Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas. Current Opinion in Neurology, 2008, 21, 728-735.	1.8	70
85	The Real Estate Factor. Stroke, 2007, 38, 194-197.	1.0	108
86	Magnetic Resonance Spectroscopy Study of Oxygen Therapy in Ischemic Stroke. Stroke, 2007, 38, 2851-2854.	1.0	77
87	A Computerized Algorithm for Etiologic Classification of Ischemic Stroke. Stroke, 2007, 38, 2979-2984.	1.0	396
88	Imaging Biomarker Applications in Oncology Drug Development. Drug Information Journal, 2007, 41, 561-572.	0.5	1
89	Advances in Imaging 2006. Stroke, 2007, 38, 238-240.	1.0	2
90	Mapping the spinal and supraspinal pathways of dynamic mechanical allodynia in the human trigeminal system using cardiac-gated fMRI. NeuroImage, 2007, 35, 1201-1210.	2.1	61

#	Article	IF	Citations
91	Abnormal cortical folding patterns within Broca's area in schizophrenia: Evidence from structural MRI. Schizophrenia Research, 2007, 94, 317-327.	1.1	69
92	Angiogenesis in brain tumours. Nature Reviews Neuroscience, 2007, 8, 610-622.	4.9	1,229
93	AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients. Cancer Cell, 2007, 11, 83-95.	7.7	1,675
94	Long-Term Monitoring of Post-Stroke Plasticity After Transient Cerebral Ischemia in Mice Using In Vivo and Ex Vivo Diffusion Tensor MRI. Open Neuroimaging Journal, 2007, 1, 10-17.	0.2	42
95	Intraoperative visualization of the pyramidal tract by diffusion-tensor-imaging-based fiber tracking. NeuroImage, 2006, 30, 1219-1229.	2.1	228
96	Strategies for improving the detection of fMRI activation in trigeminal pathways with cardiac gating. NeuroImage, 2006, 31, 1506-1512.	2.1	27
97	Transient ischemic attack with infarction: A unique syndrome?. International Congress Series, 2006, 1290, 45-55.	0.2	0
98	Future prospects for fMRI in the clinic. Journal of Magnetic Resonance Imaging, 2006, 23, 941-944.	1.9	10
99	Comparison of Manual and Automatic Section Positioning of Brain MR Images. Radiology, 2006, 239, 246-254.	3.6	47
100	Magnetic Resonance As a Cancer Imaging Biomarker. Journal of Clinical Oncology, 2006, 24, 3274-3281.	0.8	68
101	Preoperative and Intraoperative Diffusion Tensor Imaging-based Fiber Tracking in Glioma Surgery. Neurosurgery, 2005, 56, 130-138.	0.6	379
102	Applying instance-based techniques to prediction of final outcome in acute stroke. Artificial Intelligence in Medicine, 2005, 33, 223-236.	3.8	30
103	Using imaging biomarkers to accelerate drug development and clinical trials. Drug Discovery Today, 2005, 10, 259-266.	3.2	103
104	Conversion of Ischemic Brain Tissue Into Infarction Increases With Age. Stroke, 2005, 36, 2632-2636.	1.0	112
105	Imaging and Cancer: Research Strategy of the American College of Radiology Imaging Network. Radiology, 2005, 235, 741-751.	3.6	42
106	Visualization of the Pyramidal Tract in Glioma Surgery by Integrating Diffusion Tensor Imaging in Functional Neuronavigation. Zentralblatt Fur Neurochirurgie, 2005, 66, 133-141.	0.5	66
107	Intraoperative Diffusion-Tensor MR Imaging: Shifting of White Matter Tracts during Neurosurgical Proceduresâ€"Initial Experience. Radiology, 2005, 234, 218-225.	3.6	235
108	On-line automatic slice positioning for brain MR imaging. NeuroImage, 2005, 27, 222-230.	2.1	166

#	Article	IF	Citations
109	A Pilot Study of Normobaric Oxygen Therapy in Acute Ischemic Stroke. Stroke, 2005, 36, 797-802.	1.0	268
110	Imaging Angiogenesis: Applications and Potential for Drug Development. Journal of the National Cancer Institute, 2005, 97, 172-187.	3.0	312
111	Diffusion-weighted MR Imaging in Closed Head Injury: High Correlation with Initial Glasgow Coma Scale Score and Score on Modified Rankin Scale at Discharge. Radiology, 2004, 233, 58-66.	3.6	181
112	Perfusion-weighted magnetic resonance imaging of the brain: techniques and application in children. European Radiology, 2004, 14, 59-72.	2.3	61
113	MRI measurements of water diffusion: impact of region of interest selection on ischemic quantification. European Journal of Radiology, 2004, 51, 195-201.	1.2	14
114	Evolution of water diffusion and anisotropy in hyperacute stroke: significant correlation between fractional anisotropy and T2. American Journal of Neuroradiology, 2004, 25, 699-705.	1.2	45
115	Characterization and evolution of diffusion MR imaging abnormalities in stroke patients undergoing intra-arterial thrombolysis. American Journal of Neuroradiology, 2004, 25, 951-7.	1.2	34
116	Diffusion tensor imaging as potential biomarker of white matter injury in diffuse axonal injury. American Journal of Neuroradiology, 2004, 25, 370-6.	1.2	327
117	Do Highly Concentrated Gadolinium Chelates Improve MR Brain Perfusion Imaging? Intraindividually Controlled Randomized Crossover Concentration Comparison Study of 0.5 versus 1.0 mol/L Gadobutrol. Radiology, 2003, 226, 880-888.	3.6	74
118	Guidelines and Recommendations for Perfusion Imaging in Cerebral Ischemia. Stroke, 2003, 34, 1084-1104.	1.0	284
119	Biomarkers in Imaging: Realizing Radiologyâ€™s Future. Radiology, 2003, 227, 633-638.	3.6	148
120	Diffusion-Weighted Imaging for the Evaluation of Diffuse Axonal Injury in Closed Head Injury. Journal of Computer Assisted Tomography, 2003, 27, 5-11.	0.5	215
121	Assessing tissue viability with MR diffusion and perfusion imaging. American Journal of Neuroradiology, 2003, 24, 436-43.	1.2	110
122	CT and Conventional and Diffusion-weighted MR Imaging in Acute Stroke: Study in 691 Patients at Presentation to the Emergency Department. Radiology, 2002, 224, 353-360.	3.6	323
123	Comparison of Permeability in High-Grade and Low-Grade Brain Tumors Using Dynamic Susceptibility Contrast MR Imaging. American Journal of Roentgenology, 2002, 178, 711-716.	1.0	209
124	Magnetic Resonance Perfusion-Weighted Imaging of Acute Cerebral Infarction. Stroke, 2002, 33, 87-94.	1.0	126
125	The potential of proton magnetic resonance spectroscopy (1H-MRS) in the diagnosis and management of patients with brain tumors. Current Opinion in Oncology, 2002, 14, 292-298.	1.1	46
126	DT-MRI of Central Nervous System: Clinical Applications. CNS Spectrums, 2002, 7, 535-542.	0.7	0

#	Article	IF	Citations
127	Diffusion magnetic resonance imaging of acute ischemic stroke. Seminars in Roentgenology, 2002, 37, 219-229.	0.2	4
128	Diffusion-weighted MRI in diffuse axonal injury of the brain. European Radiology, 2002, 12, 2536-2541.	2.3	111
129	Iron-induced susceptibility effect at the globus pallidus causes underestimation of flow and volume on dynamic susceptibility contrast-enhanced MR perfusion images. American Journal of Neuroradiology, 2002, 23, 1022-9.	1.2	14
130	Predicting cerebral ischemic infarct volume with diffusion and perfusion MR imaging. American Journal of Neuroradiology, 2002, 23, 1785-94.	1.2	103
131	Measurement of Brain Tumor Volumes by the Perimeter Method. Journal of Clinical Oncology, 2001, 19, 3159-3160.	0.8	3
132	Comparison of Diameter and Perimeter Methods for Tumor Volume Calculation. Journal of Clinical Oncology, 2001, 19, 551-557.	0.8	239
133	Predicting Tissue Outcome in Acute Human Cerebral Ischemia Using Combined Diffusion- and Perfusion-Weighted MR Imaging. Stroke, 2001, 32, 933-942.	1.0	266
134	Frequency and Clinical Context of Decreased Apparent Diffusion Coefficient Reversal in the Human Brain. Radiology, 2001, 221, 43-50.	3.6	121
135	Technology and Archives in Radiology Research. American Journal of Roentgenology, 2001, 177, 1281-1284.	1.0	13
136	Ischemic Stroke: Effects of Etiology and Patient Age on the Time Course of the Core Apparent Diffusion Coefficient. Radiology, 2001, 221, 27-34.	3.6	110
137	Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 4687-4692.	3.3	1,312
138	What is the meaning of quantitative CBF?. American Journal of Neuroradiology, 2001, 22, 235-6.	1.2	21
139	Combined Diffusion-Weighted and Perfusion-Weighted Flow Heterogeneity Magnetic Resonance Imaging in Acute Stroke. Stroke, 2000, 31, 1097-1103.	1.0	83
140	Diffusion- and Perfusion-Weighted Magnetic Resonance Imaging in Human Acute Ischemic Stroke: Technical Considerations. Topics in Magnetic Resonance Imaging, 2000, 11, 259-272.	0.7	27
141	Human Acute Cerebral Ischemia: Detection of Changes in Water Diffusion Anisotropy by Using MR Imaging. Radiology, 1999, 212, 785-792.	3.6	289
142	Diffusion-weighted MR Imaging: Diagnostic Accuracy in Patients Imaged within 6 Hours of Stroke Symptom Onset. Radiology, 1999, 210, 155-162.	3.6	572
143	Diffusion-weighted MR imaging in acute stroke: theoretic considerations and clinical applications.. American Journal of Roentgenology, 1999, 173, 1459-1467.	1.0	135
144	Hyperacute Stroke: Simultaneous Measurement of Relative Cerebral Blood Volume, Relative Cerebral Blood Flow, and Mean Tissue Transit Time. Radiology, 1999, 210, 519-527.	3.6	410

#	Article	IF	Citations
145	Early changes measured by magnetic resonance imaging in cerebral blood flow, blood volume, and blood-brain barrier permeability following dexamethasone treatment in patients with brain tumors. Journal of Neurosurgery, 1999, 90, 300-305.	0.9	152
146	Diffusion- and Perfusion-Weighted Imaging in Vasospasm After Subarachnoid Hemorrhage. Stroke, 1999, 30, 599-605.	1.0	123
147	Modeling Cerebral Blood Flow and Flow Heterogeneity from Magnetic Resonance Residue Data. Journal of Cerebral Blood Flow and Metabolism, 1999, 19, 690-699.	2.4	128
148	A Phase 1-2 Clinical Trial of Gene Therapy for Recurrent Glioblastoma Multiforme by Tumor Transduction with the Herpes Simplex Thymidine Kinase Gene Followed by Ganciclovir. Human Gene Therapy, 1999, 10, 2325-2335.	1.4	246
149	Advanced MR techniques: diffusion MR imaging, perfusion MR imaging, and spectroscopy. Neuroimaging Clinics of North America, 1999, 9, 439-53.	0.5	19
150	Perfusion-weighted imaging defects during spontaneous migrainous aura. Annals of Neurology, 1998, 43, 25-31.	2.8	317
151	Time Course of Lesion Development in Patients With Acute Stroke. Stroke, 1998, 29, 2268-2276.	1.0	362
152	Regional Ischemia and Ischemic Injury in Patients With Acute Middle Cerebral Artery Stroke as Defined by Early Diffusion-Weighted and Perfusion-Weighted MRI. Stroke, 1998, 29, 939-943.	1.0	269
153	Magnetic resonance imaging of cerebral infarction. Topics in Magnetic Resonance Imaging, 1998, 9, 199-207.	0.7	1
154	Contrast agents in functional MR imaging. Journal of Magnetic Resonance Imaging, 1997, 7, 47-55.	1.9	109
155	Contrast-to-noise ratio in functional MRI of relative cerebral blood volume with sprodiamide injection. Journal of Magnetic Resonance Imaging, 1997, 7, 523-527.	1.9	32
156	High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part II: Experimental comparison and preliminary results. Magnetic Resonance in Medicine, 1996, 36, 726-736.	1.9	805
157	Hyperacute stroke: evaluation with combined multisection diffusion-weighted and hemodynamically weighted echo-planar MR imaging.. Radiology, 1996, 199, 391-401.	3.6	763
158	Time course of diffusion imaging abnormalities in human stroke. Stroke, 1996, 27, 1254-6.	1.0	51
159	Functional MR of brain activity and perfusion in patients with chronic cortical stroke. American Journal of Neuroradiology, 1995, 16, 1753-62.	1.2	21
160	Computed Tomography of the Body with Magnetic Resonance Imaging. Journal of Vascular and Interventional Radiology, 1993, 4, 346.	0.2	0
161	Overall body fat and regional fat distribution in young women: quantification with MR imaging.. American Journal of Roentgenology, 1991, 157, 99-104.	1.0	28
162	The role of ferritin and hemosiderin in the MR appearance of cerebral hemorrhage: a histopathologic biochemical study in rats. American Journal of Neuroradiology, 1990, 11, 291-7.	1.2	36